Skip to content
GLP1-US
Prices checked Wegovy pill $149 Wegovy pen $349 Zepbound $299–449 Foundayo from $149 Ozempic $349 Medicare Bridge $50 Compounded sema $175 All prices →

Tirzepatide explained · label checked Oct 2026

What Is Tirzepatide? Mounjaro, Zepbound and the Data

Tirzepatide is a once-weekly injected peptide that activates both GIP and GLP-1 receptors. Lilly sells it as Mounjaro for type 2 diabetes and Zepbound for weight loss, where adults lost 15.0% to 20.9% at 72 weeks.

PlushCare: visit $129 self-pay or a copay; $19.99/mo membership. Zepbound from $299/mo at LillyDirect.

  • Dual GIP + GLP-1
  • FDA-approved as Zepbound and Mounjaro
  • "Research peptide" vials: not FDA-approved
  • Prescription required

We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure

By GLP1-US Editorial TeamUpdated
★ Editor's Choice
Chia Health logo

Chia Health

Our #1 pick for GLP-1 weight loss online

  • One monthly price: clinician, medication and free shipping included
  • Semaglutide or tirzepatide, as a weekly injection or a daily tablet
  • No insurance needed; HSA/FSA and Klarna accepted

Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure

$212.89 first month, then $349/mo

6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.

Get Started Read our Chia Health review

01 The drug

What Is Tirzepatide?

Short answer: tirzepatide is the active ingredient in Mounjaro and Zepbound. The FDA label describes it as "a GIP receptor and GLP-1 receptor agonist", which means it switches on the receptors for two gut hormones that are released after you eat.

GLP-1 is the hormone behind semaglutide (Ozempic, Wegovy): it slows stomach emptying and turns down appetite. GIP is the second hormone, and tirzepatide was the first approved drug to target both. The label says the drug lowers calorie intake and body weight "with greater fat mass loss than lean mass loss" (label section 12.2).

Hormone receptors
2
GIP and GLP-1, one molecule
Shots a week
1
subcutaneous, same day each week
Strengths
6
2.5, 5, 7.5, 10, 12.5 and 15 mg

Because it hits two targets, tirzepatide is often called a "dual agonist" or, loosely, a "twincretin". Whether it counts as a GLP-1 drug: yes, a dual one; the detailed answer is on is Zepbound a GLP-1.

02 Brands

Mounjaro vs Zepbound: Same Tirzepatide, Two FDA Labels

The molecule and the strengths are identical. What differs is the approved use, and that decides insurance, Medicare and price.

FeatureMounjaroZepbound
Active ingredient tirzepatide tirzepatide
FDA approved for Type 2 diabetes (adults and children 10+); lowering heart attack, stroke and CV death risk in adults with type 2 diabetes at high CV risk (Aug 2026) Weight reduction and long-term maintenance in adults with obesity, or overweight plus a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity
First approval May 13, 2022 Nov 8, 2023 (sleep apnea Dec 20, 2024)
Forms Single-dose pen, single-dose vial, multi-dose vial, KwikPen Single-dose pen, single-dose vial, multi-dose vial, KwikPen
Maintenance dose Set by prescriber, up to 15 mg (10 mg max in children) 5, 10 or 15 mg for weight; 10 or 15 mg for sleep apnea
Self-pay No LillyDirect cash price; savings card $499 minimum without coverage $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) with a refill within 45 days
Medicare Part D for diabetes GLP-1 Bridge: $50/mo, KwikPen only, Jul 1, 2026 to Dec 31, 2027

Mounjaro and Zepbound prescribing information (both rev. 08/2026); prices from Lilly (Eli Lilly), checked Oct 17, 2026. The Zepbound label says not to combine it with any other tirzepatide product or GLP-1 drug.

Using Mounjaro for weight loss without diabetes is off-label, and the savings card needs an approved use. Deep dives: Mounjaro, Mounjaro cost, Zepbound cost and the Zepbound hub.

03 Results

Tirzepatide Weight Loss: SURMOUNT-1 Label Numbers

Short answer: in the 72-week trial behind Zepbound (SURMOUNT-1, "Study 1" on the label), 2,539 adults without diabetes lost an average of 15.0%, 19.5% and 20.9% of body weight on 5, 10 and 15 mg, against 3.1% on placebo. Everyone also got diet and activity counseling.

Share of people reaching each weight-loss mark, Study 1

Lost at leastPlacebo5 mg10 mg15 mg
5% 34.5% 85.1% 88.9% 90.9%
10% 18.8% 68.5% 78.1% 83.5%
15% 8.8% 48.0% 66.6% 70.6%
20% 3.1% 30.0% 50.1% 56.7%
Average starting weight
104.8 kg
about 231 lb
Average loss on 15 mg
about 48 lb
20.9% of 104.8 kg, our arithmetic
With type 2 diabetes (Study 2)
-12.8% / -14.7%
10 / 15 mg at 72 weeks

People with type 2 diabetes lost less on the same doses. In the head-to-head SURMOUNT-5 trial (NEJM 2025), tirzepatide averaged 20.2% weight loss versus 13.7% on semaglutide 2.4 mg at 72 weeks. Trial averages are not a promise for any one person: 14% to 16% of people on tirzepatide stopped the drug during Study 1.

Week-by-week and dose detail on Zepbound results; the full matchup on tirzepatide vs semaglutide.

04 The peptide question

Is Tirzepatide a Peptide?

Is tirzepatide a peptide?

Yes. It is a synthetic peptide, a chain of amino acids built on the natural GIP hormone sequence. Lilly swapped in two non-standard amino acids (aminoisobutyric acid) and attached a C20 fatty diacid chain, which binds to albumin in the blood and stretches the half-life to about 5 days (label sections 11 and 12.3). That is why one shot lasts a week.

Is it a protein or a hormone?

It is a peptide drug, not a natural hormone. The label lists a molecular weight of 4,813.53 Da and the formula C225H348N48O68. Your body breaks it down like other peptides, by cutting the peptide backbone.

So is "peptide" tirzepatide from a peptide shop the same thing?

No. The word "peptide" describes the chemistry, not the product. FDA-approved tirzepatide comes only as Mounjaro and Zepbound, made by Lilly under a manufacturing process FDA has reviewed. Vials sold online as "research peptides" are a different category, covered in the next section.

05 Research peptides

"Research Peptide" Tirzepatide Online: What FDA Says

Sites that sell tirzepatide "for research use only" or "not for human consumption" are not pharmacies. On Aug 24, 2026 FDA sent warning letters to five online peptide sellers whose catalogs included tirzepatide, semaglutide and retatrutide. FDA wrote that "evidence obtained from your website establishes that your products are intended to be drugs for human use" and classed them as unapproved new drugs. The same applies to "tirzepatide pills" and sublingual drops: no oral tirzepatide is FDA-approved (is there a Zepbound pill?).

  • No prescription or clinician visit required

  • "Research use only", "not for human or veterinary use" or "lab use" on the vial or page

  • Sold as powder with bacteriostatic water for you to mix

  • Payment by crypto, Zelle or gift card

  • No US pharmacy license or NABP-verified pharmacy behind the order

Why it matters: FDA notes that injected products go straight into the body and "bypass some of the body's key defenses against toxins". With a research vial, the dose, purity and sterility are unknown. If you have used one, stop and talk with a licensed prescriber. Background: risks of unregulated weight-loss peptides and the FDA warning letters to peptide sellers.

06 Compounded status

Compounded Tirzepatide After the Shortage Ended

Compounded tirzepatide is not FDA-approved and is not the same as Zepbound or Mounjaro. Pharmacies were allowed to copy it widely only while it was on FDA's shortage list; since it came off, each step has narrowed what they may sell.

  1. Dec 15, 2022

    Tirzepatide (Mounjaro) added to FDA's drug shortage list

  2. Oct 2, 2024

    FDA declares the tirzepatide shortage resolved

  3. Dec 19, 2024

    After a re-review, FDA reaffirms the shortage is over

  4. Feb 18, 2025

    End of FDA's grace period for 503A pharmacies compounding tirzepatide

  5. Mar 19, 2025

    End of the grace period for 503B outsourcing facilities

  6. May 1, 2026

    FDA proposes keeping tirzepatide off the 503B bulks list (not final as of Oct 2026)

  7. Aug 27, 2026

    The 5th Circuit upholds FDA's shortage decision

  8. Sept 18, 2026

    FDA warning letter to Empower Pharmacy over its compounded tirzepatide products

  9. Oct 1, 2026

    Two Chinese ingredient makers for compounders placed on Import Alert 66-40

Some telehealth clinics still sell compounded tirzepatide as patient-specific 503A prescriptions; across 14 providers the October 2026 median was $222 a month. Full status and price ranges: compounded tirzepatide and the GLP-1 shortage tracker. The semaglutide side of the same story: compounded semaglutide side effects and evidence. Price, FDA status and quality against the brands: compounded vs brand GLP-1.

07 Topics

Where to Go Next on Tirzepatide

This page is the overview. Each card hands off to the page that owns the topic.

08 Getting it

How to Get FDA-Approved Tirzepatide

  1. 1

    Check the fit.

    Zepbound is for adults with a BMI of 30 or more, or 27 or more with a weight-related condition. Find your number with the BMI calculator.

  2. 2

    Get a prescription.

    Your own doctor or a telehealth clinic. Online programs that prescribe brand Zepbound include PlushCare, Ro and Amazon One Medical.

  3. 3

    Pick how you pay.

    Commercial insurance with the savings card (as little as $25), LillyDirect self-pay at $299 to $449 a month, or the Medicare GLP-1 Bridge at $50 a month if you qualify.

Ro: membership plus Zepbound, about $373/mo at 2.5 mg on the 12-month plan. Amazon One Medical prescribes and Amazon Pharmacy fills the Zepbound KwikPen; the Bridge copay is set by Medicare, not by the provider. Program prices as listed by each provider and Lilly on Nov 17, 2026. A clinician decides whether tirzepatide fits you.

09 FAQ

Tirzepatide FAQ

What is tirzepatide used for?
Tirzepatide has four FDA-approved uses as of October 2026. As Mounjaro, it treats type 2 diabetes in adults and children 10 and older and lowers heart attack and stroke risk in adults with diabetes at high cardiovascular risk. As Zepbound, it is approved for weight loss and maintenance in adults with obesity or overweight plus a related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.
Is tirzepatide a peptide?
Yes. Tirzepatide is a synthetic peptide based on the GIP hormone sequence, with a fatty acid chain attached so it binds to albumin and lasts about 5 days, which is why it is dosed once a week. Being a peptide does not make every "peptide" vial legal: only Mounjaro and Zepbound are FDA-approved, and FDA calls research-use tirzepatide sold online an unapproved drug.
How much weight can you lose on tirzepatide?
In the 72-week SURMOUNT-1 trial, adults without diabetes lost an average of 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo. On 15 mg, 56.7% lost at least 20% of body weight. Adults with type 2 diabetes lost 12.8% to 14.7%. Averages vary by person and assume diet and activity changes too.
Is tirzepatide the same as Zepbound?
Zepbound is a brand of tirzepatide, and so is Mounjaro. Both contain the same molecule in the same six strengths, from 2.5 to 15 mg once a week. Zepbound carries the weight-loss and sleep apnea approval; Mounjaro carries the diabetes approval. Zepbound costs $299 to $449 a month self-pay through LillyDirect as of October 2026, and Mounjaro has no LillyDirect cash price.
Is compounded tirzepatide still legal?
Only in narrow cases. FDA ended the tirzepatide shortage on Oct 2, 2024, the grace periods for compounders ended in February and March 2025, and the 5th Circuit upheld FDA's decision on Aug 27, 2026. Some 503A pharmacies still fill patient-specific prescriptions. Compounded tirzepatide is not FDA-approved, and FDA warned Empower Pharmacy about its tirzepatide products on Sept 18, 2026.
Is tirzepatide safe?
Tirzepatide is FDA-approved, with known risks. The most common side effects are stomach-related: nausea hit 25% to 29% of people on Zepbound doses versus 8% on placebo. The label carries a boxed warning about thyroid C-cell tumors seen in rats and warns about pancreatitis and gallbladder disease. Safety data cover the branded drug only.

Safety in more depth, for semaglutide and tirzepatide: is tirzepatide safe.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.

Checked against primary sources such as FDA labels, CMS and provider pages
Updated
How we check facts →